Return to Drug Transparency Home Page:
Subscribe/Unsubscribe to LISTSERV email notifications for Nevada Drug Transparency Information and Updates Here:
Drug Transparency - Essential Lists, Reports & Resources
extended the April 1st reporting deadline due to COVID-19. Due to
this extension, DHHS will be delaying the posting of the June 1st
report as we want to provide the most accurate and complete report possible. We
apologize for the delay and will update this page with the new deadline
date when it is available.
Essential Diabetes and Asthma Drug List ~ NRS 439B.630
Senate Bill No. 539 was passed during the 2017 legislative session, requiring the Department to compile a list of prescription drugs that the Department determines to be essential for treating diabetes in this State and the wholesale acquisition cost of each drug on the list. Effective May 30, 2019, Senate Bill No. 262 builds on Nevada’s diabetes drug pricing transparency law by including asthma drugs. The list must include, without limitation, all forms of insulin and biguanides marketed for sale in this State.
Drug Pricing Report ~NRS 439B.635
Senate Bill No. 539 was passed during the 2017 legislative session, requiring the Department to analyze the information submitted pursuant to sections 3.8, 4 and 4.2 of this act and compile a report on the price of the prescription drugs that appear on the most current lists compiled by the Department pursant to section 3.6 of this act, the reasons for any increase in those prices and the effect of those prices on overall spending on prescription drugs in the State. The report may include, without limitation, opportunities for persons and entities in this State to lower the cost of drugs for the treatment of diabetes while maintaining access to such drugs.
Pharmaceutical Sales Representatives Report ~ NRS 439B.660
Senate Bill No. 539 was passed during the 2017 legislative session, requiring the Department to compile a report on the activities of pharmaceutical sales representatives in this state with a list of prescription drugs used to treat diabetes and requiring each pharmaceutical sales representative to report samples as well as compensation in excess of $10 provided to health care providers within the State of Nevada.
Drug Transparency Statutes and Regulations